[Temporary Announcement] Kangyuantang: Announcement of Resolutions of the Fourth Extraordinary Shareholders Meeting in 2025
Announcement number: 2025-068
Securities code: 873173 Securities abbreviation: Kangyuantang Sponsoring broker: Zhongtai Securities
Shandong Kangyuantang Pharmaceutical Co., Ltd.
Announcement of Resolutions of the Fourth Extraordinary Shareholders Meeting in 2025
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
1. Meeting convening and attendance
(1) Meeting status
Meeting time: December 30, 2025
Meeting method: √On-site meeting □Electronic communication meeting
The meeting will be held at Building 17, High-tech Industrial Park, No. 30 Dongfeng East Road, Weishan County, Jining City, Shandong Province. 3. Meeting voting method:
√On-site voting □Electronic communication voting
□Online voting □Other ways to vote
Meeting convener: Board of Directors
Meeting host: Mr. Zhou Changlin, Chairman
Explanation on the legality and compliance of the convening situation:
The convening and procedures of this general meeting of shareholders complied with the relevant provisions of the Company Law and the Articles of Association.
(2) Meeting attendance
A total of 6 shareholders attended and authorized to attend this shareholders' meeting, holding a total of 93,999,200 shares with voting rights, accounting for 99.9991% of the company's total voting shares.
(3) Attendance of the company’s directors, supervisors and senior managers at the shareholders’ meeting
- The company has 7 current directors and 7 non-voting directors;
Announcement number: 2025-068
The company has 0 serving supervisors and 0 people attending;
The secretary of the company’s board of directors attends the meeting;
There are no other attendees.
2. Proposal review status
(1) Consideration and approval of the "Proposal on Electing Ms. Qin Zhaoxia as an Independent Director of the Fourth Board of Directors"
- Contents of the motion:
In order to improve the corporate governance structure, according to the company's articles of association, the board of directors intends to nominate Ms. Qin Zhaoxia as an independent director candidate for the company's board of directors. The term of independent director shall be from the date of review and approval by the shareholders' meeting to the expiration date of the fourth term of the board of directors.
- Proposal voting results:
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
- Avoid voting situations
This motion does not involve avoidance of voting.
(2) Consideration and approval of the "Proposal on Electing Ms. Liu Yingfang as an Independent Director of the Fourth Board of Directors"
- Contents of the motion:
In order to improve the corporate governance structure, according to the company's articles of association, the board of directors intends to nominate Ms. Liu Yingfang as an independent director candidate for the company's board of directors. The term of independent director shall be from the date of review and approval by the shareholders' meeting to the expiration date of the fourth term of the board of directors.
- Proposal voting results:
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
- Avoid voting situations
This motion does not involve avoidance of voting.
Announcement number: 2025-068
(3) Consideration and approval of the "Proposal on Establishing the Audit Committee of the Board of Directors and Electing Members of the Audit Committee" 1. Contents of the proposal:
In order to improve the company's decision-making procedures and further improve the corporate governance structure, in accordance with the "Company Law of the People's Republic of China", the "Governance Rules for Companies Listed on the National Equities Exchange and Quotations" and the "Articles of Association of Shandong Kangyuantang Pharmaceutical Co., Ltd.", Shandong Kangyuantang Pharmaceutical Co., Ltd. decided to set up an audit committee under the board of directors to exercise the working powers of the original board of supervisors.
The Audit Committee of the Board of Directors consists of three directors who are not senior management members of the Company. There are 2 independent directors, and accounting professionals among the independent directors serve as the convener.
Independent director Qin Zhaoxia, independent director Liu Yingfang and director He Jiachang are now nominated as members of the audit committee, and independent director Qin Zhaoxia is appointed as the convener of the audit committee. The terms of office of the members of the Audit Committee will end on the expiration date of the term of the current board of directors. Among them, the qualifications of independent director Qin Zhaoxia, independent director Liu Yingfang, and director He Jiachang will take effect after being reviewed and approved by the shareholders' meeting.
- Proposal voting results:
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
- Avoid voting situations
This motion does not involve avoidance of voting.
(4) "Proposal on Amending the Company's Relevant Systems (which still needs to be submitted to the shareholders' meeting for review)"
- Proposal voting results:
(1) Review and approve the "Rules of Procedure for the Shareholders' Meeting"
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
(2) Review and adopt the Rules of Procedure for the Board of Directors
The number of common shares approved was 93,999,200 shares, accounting for 100% of the total number of shares with voting rights present at this meeting;
Announcement number: 2025-068
The number of opposing shares was 0, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
(3) Review and adopt the "External Guarantee Management System"
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
(4) Review and adopt the "Foreign Investment Management System"
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
(5) Review and approve the “Related Transaction Management System”
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
(6) Review and approve the "Raised Funds Management System"
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
(7) Review and approve the "Profit Distribution Management System"
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
(8) Review and approve the "Commitment Management System"
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
(9) Review and approve the “Investor Relations Management System”
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights attending this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights attending this meeting; the number of abstaining shares was 0 shares, accounting for 0.
Announcement number: 2025-068
0% of the total number of shares with voting rights attending this meeting.
(10) Review and approve the "Independent Director System"
The number of common shares agreed was 93,999,200, accounting for 100% of the total number of shares with voting rights present at this meeting; the number of objections was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting; the number of abstaining shares was 0 shares, accounting for 0% of the total number of shares with voting rights present at this meeting.
- Refusal to vote
This motion does not involve avoidance of voting.
3. Effectiveness of the proposals for changes in directors, supervisors and senior managers reviewed at this meeting
Name Position title Changes Effective date Name of meeting Effectiveness Qin Chao Independent Director Appointed 2025-12-30 2025 Fourth interim review and approval
Xia Shi shareholders meeting
Liu Ying Independent Director Appointed on 2025-12-30 Approved at the fourth interim review in 2025
Fangshi shareholders meeting
4. Documents for reference
"Resolution of the Fourth Extraordinary Shareholders Meeting of Shandong Kangyuantang Pharmaceutical Co., Ltd. in 2025"
Board of Directors of Shandong Kangyuantang Pharmaceutical Co., Ltd.
December 30, 2025